# Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

> **NCT07129772** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The University of Hong Kong** · enrollment: 53 (estimated)

## Conditions studied

- Nasopharyngeal Cancer Recurrent
- Nasopharyngeal Cancinoma (NPC)

## Interventions

- **DRUG:** Gemcitabine (GEM)
- **DRUG:** Cisplatin
- **DRUG:** PEMBROLIZUMAB (alone or when added to a regimen above)

## Key facts

- **NCT ID:** NCT07129772
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-11-01
- **Primary completion:** 2027-12-31
- **Final completion:** 2028-06-30
- **Target enrollment:** 53 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07129772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07129772, "Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07129772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*